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Evaluation of Phage Display Discovered Peptides as
Ligands for Prostate-Specific Membrane Antigen (PSMA)
Duanwen Shen1., Fei Xie2., W. Barry Edwards2*
1 Radiology, Washington University, St. Louis, Missouri, United States of America, 2 Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Abstract
The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted
peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation
with a 15-mer phage display random peptide library. After one round of prescreening and two rounds of screening, highstringency screening at the third round of panning was performed to identify the highest affinity binders. Phages which had
a specific binding activity to PSMA in human prostate cancer cells were isolated and the DNA corresponding to the 15-mers
were sequenced to provide three consensus sequences: GDHSPFT, SHFSVGS and EVPRLSLLAVFL as well as other sequences
that did not display consensus. Two of the peptide sequences deduced from DNA sequencing of binding phages,
SHSFSVGSGDHSPFT and GRFLTGGTGRLLRIS were labeled with 5-carboxyfluorescein and shown to bind and co-internalize
with PSMA on human prostate cancer cells by fluorescence microscopy. The high stringency requirements yielded peptides
with affinities KD,1 mM or greater which are suitable starting points for affinity maturation. While these values were less
than anticipated, the high stringency did yield peptide sequences that apparently bound to different surfaces on PSMA.
These peptide sequences could be the basis for further development of peptides for prostate cancer tumor imaging and
therapy.
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cell, and pancreas cancers [9,10]. However, it is not expressed in
normal vasculature [10,11]. Interestingly, the average serum
PSMA value for prostate cancer was significantly higher (P,0.001)
than that for benign prostate hyperplasia and the normal groups
[7]. Recently, a radiolabeled monoclonal antibody (MAb) to
PSMA named J591, was used for non-invasive imaging and
radiotherapy for prostate cancer in human subjects with positive
results [12,13,14]. PSMA on the cell surface is internalized by J591
[15] and endocytosed through clathrin coated pits, though the
natural ligand of PSMA is unknown. Therefore PSMA targeting
can play an important role in directing the treatment and
therapeutic options for patients with prostate cancer.
Monoclonal antibodies may appear to be ideal imaging agents
because of their high specificity and affinity for the target epitopes,
but their most serious shortcoming is their very long plasma halflives which ultimately set optimal signal to noise at days post
administration. For example, the optimal imaging time of 111InMab 7E11 is 96 h post-administration [16]. For this reason, low
molecular weight ligands are sought for their more favorable
pharmacokinetics. Small hydrophilic inhibitors of the enzymatic
domain of PSMA have been either labeled with 18F and 68Ga for
molecular imaging of PSMA by positron emission tomography or
with 99mTc single photon emission computed tomography
[17,18,19,20]. Additionally, these potent inhibitors have been
labeled with near infrared dyes for optical imaging [21,22]. All of

Introduction
Prostate cancer (PCa) is the second leading cause of death in
men in the United States and is the most diagnosed cancer in men.
If diagnosed early, the five year survival rate is very good. The
implementation of prostate specific antigen (PSA) screening, which
facilitates earlier detection of prostate cancer, is partly responsible
for the decrease in mortality [1,2]. However, PSA levels are not an
accurate predictor of the aggressiveness of prostate cancer, with
the PSA rate of change (PSA velocity) not able to discriminate
between men with cancer and those with negative biopsies [3,4,5].
On the contrary, there are high frequencies of prostate-specific
membrane antigen (PSMA) overexpression in all stages and grades
of PCa patients. The overexpression of PSMA was significantly
associated with tumor stage, where the higher Gleason graded
tumors corresponded with higher expression levels of PSMA [6,7].
Therefore, PSMA is an alternative to PSA as a diagnostic
biomarker for detection of PCa [6].
PSMA is a 100-kDa transmembrane glycoprotein with folate
hydrolase activity (hydrolysis of the terminal glutamates from clinked polyglutamates) as well as NAALADase activity (hydrolysis
of the terminal glutamate from the neuropeptide NAAG), which
was found not only in normal prostate epithelium but also in the
central nervous system and the proximal gastrointestinal tract [8].
PSMA is also overexpressed in the neovascular endothelium of
most solid tumors, including lung, colon, breast, renal, transitional
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Chem-Impex International (Wood Dale, IL). The 5-FAM (5carboxyfluorescein) was purchased from AnaSpec (Fremont, CA).
The AlphaScreen Histidine detection kit which contains the
streptavidin donor beads and the nickel chelate acceptor beads
was purchased from PerkinElmer (Waltham, MA). All other
reagents were purchased from Sigma Aldrich (St. Louis, MO).

the analogs have exhibited PSMA-mediated tumor uptake in
animal models with low non-target tissue uptake except for kidney.
As of yet, however, there have been no reported peptides of high
affinity that are suitable for PSMA imaging. Peptides have
displayed pharmacokinetics suitable for imaging patients on the
same day as administration with good target tissue uptake and low
non-target tissue uptake. (reviewed in [23]) Unlike small molecule
inhibitors, peptides are biopolymers that are easily accessible by
solid-phase synthesis from readily available starting materials.
Furthermore, they are generally structurally more robust than
antibodies and are suitable surrogates with affinity sufficient for
molecular imaging. Consequently the discovery of peptides with
high affinity for PSMA would be of benefit for anti-prostate cancer
research.
One way of finding peptides for a ligand is through panning of a
phage-displayed peptide library for the ligand of interest. Phage
display is a technique where random peptides are fused to the coat
protein of a bacteriophage in a manner that makes them accessible
to target ligands. The DNA encoding the peptide sequence is
protected within the virion [24]. Panning is a technique of
successive binding, rinsing, and elution of specifically bound phage
to target receptors. This will result in enrichment of peptideligands with stronger affinity for the target receptor.
The goal of this research was to find lead peptide sequences that
bind PSMA for further development as imaging agents for
targeted therapy by screening a library of phage displayed
peptides against PSMA. A 15-mer library was screened against
the soluble ectodomain of PSMA. In the initial step, the library
was pre-cleared by intravenous administration in a mouse to
remove phages that bound to vascular proteins thus clearing the
phage pool of non-specific binders. The resulting library was then
screened against the soluble ectodomain of PSMA under low
stringency conditions for two rounds of affinity based selection
followed by one round of high stringency selection. The purpose of
the high stringency selection was to direct selection toward highaffinity binders. Nine unique sequences were determined from
twelve isolated phage clones. These sequences were tested for
specificity toward PSMA expressed on human prostate cancer cells
and the binding affinity was quantified by AlphaScreen and
PSMA enzyme assays.

General methods
All peptides were synthesized on the CEM Liberty1 microwave
peptide synthesizer (Matthews, NC) using the Rink amide resin,
except for the biotinylated peptides which used the biotin-PEG
NovaTag resin. 5-FAM peptides were synthesized by coupling 5FAM to the N-terminus of the peptide on resin. All peptides were
purified by HPLC and the molecular weights were confirmed by
either ESI MS (Waters LCT Premier XE) or MALDI-TOF MS
(Applied Biosystems Voyager DE-STR).

Tetrameric peptide synthesis
The tetrameric peptide was synthesized as previously described
[26]. Briefly, the thiol containing reactive peptide monomer was
synthesized by introducing a GGGS-(PEG)6-C linker to the Cterminus of peptide 562 (Table 1). The maleimide-activated core
was synthesized by coupling the 3-maleimido-propionic acid on
the Fmoc4-Lys2-Lys-b-Ala Wang resin. The purified reactive
peptide monomer and the maleimide-activated core were conjugated in PBS with the final tetrameric peptide purified through
HPLC.

Screening the phage library for PSMA-targeted peptides
Standard preparations and procedures methods were described
from George P. Smith on the website http://www.biosci.missouri.
edu/SmithGP/PhageDisplayWebsite/
PhageDisplayWebsiteIndex.html) and as previously described
[27]. To deplete the library of background binding phage, the
plate was coated with monoclonal anti-polyhistidine antibody
(mouse), then 5% bovine serum albumin (BSA) without PSMAHis6. Then, 1.961013 colony-forming units (cfu) were added and
Table 1. Sequences of phage clones isolated after 3-round of
panning and IC50 values of the peptides analyzed.

Materials and Methods
Materials
F3-15mer random bacteriophage library and K91BluKan
(B91BK) E.Coli expression system was depleted of phage that
bind proteins of mouse vasculature as previously described [25].
His-tagged PSMA (PSMA-His6) was purchased from R&D
Systems. Rabbit monoclonal anti-PSMA antibody was purchased
from Epitomics (Burlingame, CA). Biotinylated rabbit polyclonal
anti-Fd bacteriophage antibody was purchased from SigmaAldrich (St. Louis, MO). Alexa 488 conjugated streptavidin was
purchased from Invitrogen (Carlsbad, CA). TRITC labeled
donkey anti-Rabbit IgG was purchased from Jackson ImmunoResearch Laboratories, INC. (West Grove, PA). TBS is 50 mM
Tris, 150 mM NaCl, pH 7.4. Fmoc-L-Amino acids, HCTU (2-(6Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate), and Cl-HOBt (6-Chloro-1-hydroxybenzotriazole) were purchased from AAPPTec (Louisville, KY). The Rink
amide AM resin LL (100–200 mesh) and the biotin-PEG NovaTag
resin were purchased from EMD Millipore (Billerica, MA). The
Fmoc4-Lys2-Lys-b-Ala Wang resin and the N-Fmoc-AmidodPEG6 acid were purchased from Peptide International (Louisville, KY). The 3-maleimido-propionic acid was purchased from
PLOS ONE | www.plosone.org
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Clone ID Sequence

#

B

LPIFKVDFGDHSPFT

nd

nd

nd

C

ARMFLLFLMRCIGCY

565*

.4.83 mM

a

D, H

SHSFSVGSGDHSPFT

562

nd

661 mM
(76 mM){
311 mM

SHSFSVGSGDHSPFT

(562)4

nd

E, F

SHSFSVGSGSGDHSP

nd

nd

nd

G

LSFFSCWLRRSFSLT

564*

1.72 mM

b

I

EVPRLSLLAVFLVVM

nd

nd

nd

J

EVPRLSLLAVFLCNG

nd

nd

nd

K, L

EVPRLSLLAVFLVAN

nd

nd

nd

M

GRFLTGGTGRLLRIS

563

708 nM

c

*Cys(Acm) in peptides 564 and 565.
Ki value from the Cheng-Prussof equation.
, no inhibition observed at 14.5 mM.
b
, no inhibition observed at 55.5 mM.
c
, no inhibition observed at 1 mM.
nd, not determined.
doi:10.1371/journal.pone.0068339.t001
{
a

2
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allowed to bind (ambient temperature, 1 h); the non-binding
phage were collected, amplified and purified for the first round of
screening.
All screening began with 1.961013 cfu and was carried out in
one well of a 6-well plate (Corning, binding capacity 2.5 mg IgG/
well) in a volume of 1.5 mL. The well was coated with mouse
monoclonal anti-polyhistidine antibody (1.5 mL, 5 mg/mL) followed by blocking (5% BSA, TBS, 3 h). PSMA-His6 was then
captured by the immobilized antibody (3 h, ambient temperature).
For rounds one and two of panning (18 h, 46C), low stringency
was used (42 nM PSMA-His6). In the third round of screening, the
stringency was increased to select for the strongest binding phage
(33 pM PSMA-His6). After rinsing to remove non-binding phages
(TBS), bound phage were eluted under acidic conditions,
neutralized, amplified and purified for the second round of
screening. Individual phage clones were selected on Kanamycin
and Ampicillin antibiotic plates and sequenced after the second
and third rounds of screening.

Determination of Cell Surface Binding and Internalization
by Confocal Microscopy
The binding and cellular internalization study of phage clones
and 5-FAM labeled peptides was performed as described
previously [28]. Briefly, LNCaP and PC-3 cells (16104 cells/well)
were grown on LabTek 8-chamber slides (Nunc Inc. Rochester,
NY) overnight prior to the experiment. To determine the binding
and internalization of phage clones, each clone (109 cfu) was
incubated with LNCaP or PC-3 cells adherent in chamber slides
(376C, 2 h). After rinsing (PBS), the cells were fixed and
permeabilized (4% paraformaldehyde, 0.01% Triton-X, 15 min)
and blocked (5% BSA, TBS). To visualize the surface bound and
internalized phage clones, the fixed and permeabilized cells were
treated with either biotinylated rabbit anti-Fd bacteriophage
antibody and Alexa 488 conjugated to streptavidin, or rabbit
monoclonal anti-PSMA antibody (primary antibody) with TRITC
labeled donkey anti-Rabbit IgG (secondary antibody). To inhibit
the specific binding of the phage clones, the cells were preincubated with PSMA-His6 (100 nM, 2 hours, 376C) before
adding the phage clones. To quantify the fluorescence, the relative
fluorescence unit (rfu) in the LNCap cells was measured with the
software in Olympus FV1000 confocal scanning microscope..

DNA sequencing
The phagemids of PSMA-bound phages were isolated (TRIzol
reagent, Invitrogen, Carlsbad, CA), purified with (phenol/chloroform) and used as templates for DNA sequencing. PCR was used
to amplify using the primer 59-TGAATTTTCTGTATGAGG-39
(reverse primer 39-ACTTAAAAGACATACTCC-59). Template
amplification was done using BigDye Terminator (V3.1, Invitrogen/Applied Biosystems, Carlsbad, CA). The PCR reaction
started at 986C for 5 minutes followed by 30 cycles of
amplification at 966C for 15 seconds, 556C for 15 seconds,
606C for 4 minutes. The DNA sequences of phages were used to
deduce the peptide sequence (Table S1). A GeneBank (BLAST)
homology search was performed of consensus sequences that
emerged from the screening to determine whether they are
homologous to motifs present in human proteins.

Cell Culture
The LNCaP and PC-3 human prostate cancer cell lines
(American Type Culture Collection, Rockville, MD) were
maintained in RPMI 1640 medium (Life Technologies, Grand
Island, NY) containing 10% fetal bovine serum (FBS; Invitrogen/
GIBCO, Carlsbad, CA), 100 U/ml penicillin, 100 mg/ml streptomycin in 5% CO2/95% air at 376C.

Figure 2. Immunofluorescence microscopy of phage clones
from round 2 of panning. (A) PSMA (100 nM) inhibited the binding
of Clone 1 (ARLSHRPSYLLVCA) and Clone 2 (GTAVASRVYSLHSLM) to
PSMA-postive LNCaP cells, indicating that the uptake was receptor
specific (scale is 30 mm). (B) Immunofluorescence microscopy of phage
clones from round 2 of panning indicate that the panning process is
biased toward PSMA binding (‘‘*’’ denotes P,0.05).
doi:10.1371/journal.pone.0068339.g002

Figure 1. Recoveries from screening phage displayed libraries
against the soluble ectodomain of PSMA.
doi:10.1371/journal.pone.0068339.g001
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Figure 4. Binding and internalization of 5FAM-562 and 5FAM563 in LNCaP cells. 5FAM-562 (1 mM, A–C, green) and 5FAM-563
(1 mM , D–F, green) bound and internalized in LNCaP cells and colocalized with PSMA in intracellular vesicles visualized with anti-PSMAMab (red, scale is 20 mm).
doi:10.1371/journal.pone.0068339.g004

second incubation (dark, ambient temperature, 1 h). Streptavidin
donor beads (5 mL, 120 mg/mL) were added for a final incubation
(dark, ambient temperature, 30 m). The amount of bound 563biotin to PSMA-His6 was quantified on a Synergy H4 hybrid
multi-mode microplate reader (Biotek) using factory recommended
settings. The final concentration for the donor/acceptor beads was
20 mg/mL, and the buffer used in this assay was 25 mM HEPES,
100 mM NaCl, pH 7.4. Data was analyzed by non-linear
regression with GraphPad Prism.

Figure 3. Immunofluorescence microscopy of phage clones
from round 3 of panning. Randomly selected PSMA-targeted phage
clones (C, E, G, H, J, L) from the third round of screening bound
specifically to LNCaP cells (‘‘L’’), but not PC3 cells (‘‘P’’). While staining
was preferentially bound at cell surface, there was evidence of
internalization (scale 20 mm).
doi:10.1371/journal.pone.0068339.g003

PSMA enzyme assay
The glutamic acid/glutamate released from the natural
substrate of PSMA, NAAG (N-acetylaspartylglutamate), was
analyzed by the fluorescence-based Amplex Red Glutamic Acid/
Glutamate Oxidase assay kit (Invitrogen) as previously described
[21,22,32,33]. Briefly, in a 96-well half area black flat bottom
polystyrene NBS microplate (Corning, Tewksbury, MA), PSMAHis6 (3 nM, 10 mL) and different concentrations of peptide 562
(monomer or tetramer, 20 mL) or buffer (TBS, 20 mL) were
incubated (376C, 30 min). Then NAAG (4 mM, 10 mL) was added
to the peptide/PSMA-His6 mixture (376C, 30 min). The enzymatic reaction was quenched (500 mM NaH2PO4/Na2HPO4,
pH 7.4, 10 mL). The fluorescence signals generated from the
Amplex working solution (50 mL) with the NAAG-liberated
glutamate (376C, 1 hour, light exclusion) were then quantified
by the Synergy H4 hybrid multi-mode microplate reader (Ex
530 nm, Em 590 nm). Data was analyzed by non-linear regression
with GraphPad Prism.

Regions of interest were drawn in ten cells to determine the rfu
values.
To determine whether the discovered peptides from the third
round of screening bound PSMA-positive LnCAP cells and cointernalized with PSMA, the 5-FAM labeled peptides
(DMSO:TBS 80:20, v/v) were diluted in culture medium (1 mM)
and incubated with adherent LNCaP cells in 8-well chamber slides
(1 h, 376C). After rinsing with PBS, the cells were fixed (4%
paraformaldehyde, 15 min) and permeabilized (0.01% Triton-X,
15 min). Non-specific binding sites were blocked (5% BSA, TBS,
1 h), and then the cells were incubated with 1:1000 rabbit
monoclonal anti-PSMA antibody (primary antibody, 3% BSA,
TBS, 1 h). After rinsing (PBS), the cells were incubated with
1:1000 TRITC labeled donkey anti-Rabbit IgG (secondary
antibody, 3% BSA, TBS, 1 h). After rinsing with PBS, the cells
were mounted (50% glycerol, PBS), covered with coverslips, and
sealed with nail polish. Confocal laser scanning microscopy
(Olympus FV1000) was used to analyze all samples. We also used
z-stack images to determine the extracellular and intracellular
locations of the 5-FAM labeled peptides.

Results and Discussion
Recoveries of phage during panning
A 15 amino acid fUSE5 phage display library was used as input
phage to screen against poly-histidine tagged PSMA (PSMA-His6)
immobilized in 6-well plates. This library had been previously
depleted of phage that bound the endothelial cells of mouse and
then re-amplified. After a depletion of the library of phage that
bound non-specifically to the selection components consisting of
BSA and anti-His6-Mab, the phage display library of 15-mers, was
panned against PSMA-His6 that was captured by immobilized
anti-His6-Mab. In rounds one and two the recovered phage was
rising which is indicative of positive selection; however, the

AlphaScreen assay
The AlphaScreen competition binding assay was performed
based on published procedures [29,30,31]. Briefly, to a 384-well,
low flange, white flat bottom polystyrene NBS microplate
(Corning, Tewksbury, MA), biotinylated peptide 563 (563-biotin,
5 mL, 600 nM), PSMA (10 mL, 30 nM) and buffer or peptide
(various concentrations, 5 mL) were added. The mixture was
incubated (ambient temperature, 1 h), and then nickel chelate
acceptor beads (5 mL, 120 mg/mL) were added followed by a
PLOS ONE | www.plosone.org
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strategy had biased the library toward PSMA binding (Figure 2).
After round 3 of selection, clones C, E, G, H, J, and L were tested
for PSMA-mediated binding to LNCaP cells. These phage clones
bound PSMA-positive LNCaP cells much more strongly than
PSMA-negative PC3 cells utilizing the same input quantities for
both cells (Figure 3). The staining is strong at the cell periphery
where PSMA is localized. In some cases, vesicles are starting to
appear on the cell periphery which is indicative of internalization,
which has been previously observed with other PSMA targeted
ligands [15]. This data indicate that the library is definitely biased
toward PSMA binding and the tested clones do indeed bind
PSMA in its natural state on human cancer cells. At this point, the
panning process was stopped and the displayed peptide sequences
were tested for further development as PSMA ligands.

recovery decreased significantly when the concentration of PSMAHis6 was decreased from 42 nM to 33 pM from the second to
third round of selection, respectively (Figure 1). The binding
capacity of the plate was ,10 nM in the capturing antibody,
therefore we exceeded the binding capacity of the plate by ,4fold, assuming a high affinity of the anti-His6-Mab for the His6 tag.
The very low concentration of PSMA (33 pM) was used to
increase the stringency of specific binding to PSMA so that only
the highest affinity peptides would be selected [34]. After the third
round of selection, three strong consensus sequences emerged:
GDHSPFT, SHFSVGS and EVPRLSLLAVFL, where the former
sequence appeared three times and the latter two sequences
appeared four times (Table 1). Consensus sequences suggest the
presence of a defined binding motif whose affinity could be
enhanced by key amino acid substitutions within or adjacent to the
consensus sequence itself. A BLAST (NCBI) search algorithm for
the sequences GDHSPFT, SHFSVGS and EVPRLSLLAVFL
revealed a number of human proteins with motifs that have
significant homology to the consensus sequences. However, there
was no obvious correlation between them and possible binding
partners for PSMA.

Co-localization of the targeted peptides and PSMA on
the surface of LNCaP cells
To further address the specificity and affinity of the discovered
peptides toward PSMA-binding among the selected phages in the
third round of screening, a total of 13 phage clones were selected
and their phagemids DNA were isolated, sequenced and deduced
to protein sequences, which were used as templates for syntheses of
the 15-mer peptides. Three consensus sequences, -SHSFSVGSG-,
-GDHSPFT- and -EVPRLSLLAVFL- were found in the screening (Table 1). Two peptides containing a consensus sequence,
SHSFSVGSGDHSPFT (562) and GRFLTGGTGRLLRIS (563),
were synthesized and conjugated with 5-carboxyl fluorescein
(5FAM) on the N-terminal amine to determine whether they
would induce internalization in LNCaP cells (Figure 4). These
results show strong co-staining between the 5FAM-562 and
5FAM-563 and PSMA located in intra- cellular vesicular
compartments within the LNCaP cells indicating that both
peptides bind PSMA and induce internalization which would be
an important attribute for molecular imaging (Figure 4)
[12,13,14]. Previously, monoclonal antibodies and small molecule
PSMA-inhibitors have been shown to be internalized into cells,
mediated by PSMA [11,36]. On phage, the peptides are
connected C-terminally to the phage and it is possible that
modifications at the N-terminus could reduce binding affinity;
however, if there was any reduction in affinity, it was not great
enough to completely inhibit binding. These results indicate that

Microscopy of phage clones
The phage displayed library was panned against soluble PSMA,
which according to structural studies, exists predominately in the
dimeric state and is fully functional in that state [35]. However, it
was not known whether the soluble homodimer would be in a
conformational state that would produce binding peptides that
would also recognize PSMA naturally expressed in human cancer
cells. To determine if the selected phage clones did recognize
PSMA in its natural state, binding of the clones was visualized by
confocal immuno-fluorescence microscopy on the human prostate
cancer cells LNCaP (PSMA positive) and PC3 (PSMA negative).
To verify that the selection was positively biased toward PSMA
selection after round 2, eight clones were selected. Clone 1
(ARLSHRPSYLLVCA) appeared once and clone 2(GTAVASRVYSLHSLM) appeared seven times. The binding of clones 1 and
2 to PSMA was tested with LNCaP cells with and without an
inhibitory concentration of PSMA-His6 (100 nM). The addition of
soluble PSMA significantly reduced binding to the LNCaP cells for
both clones (P,0.05, students t-test) indicating that the selection

Figure 5. Evaluation of binding affinities between phage display-discovered peptides and PSMA. (A) AlphaScreen assay in which
Peptide 563 (filled circles) or Peptide 564 (filled squares) competed with biotinylated peptide 563 for binding to PSMA. Data was fitted to generate
IC50 curves for Peptide 563 (solid line) and Peptide 564 (dashed line). (B) Fluorescence-based PSMA enzyme inhibition assay in which Peptide 562
monomer (filled circles) or Peptide 562 tetramer (filled squares) inhibited the hydrolysis of NAAG (substrate) by PSMA. Data was fit to generate IC50
curves for Peptide 562 monomer (solid line) and Peptide 562 tetramer (dashed line).
doi:10.1371/journal.pone.0068339.g005
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Figure 6. Structure of the Peptide 562 tetramer.
doi:10.1371/journal.pone.0068339.g006

place 563-biotin in a log dose-dependent manner. In control
experiments peptide 562 generated high background counts due to
nickel binding (through histidines) properties and was thus not
suited for analysis by AlphaScreen but did inhibit the PSMA
enzymatic reaction (against 1 mM NAAG) and gave an IC50 value
of 661 mM (95% confidence intervals: 426–1024 mM, Figure 5B).
Utilizing the Cheng-Prusoff equation, KI = IC50/(1 + [S]/KM)
and KM = 0.13 mM, a KI value of 76 mM can be computed [39].
Peptide 565 was relatively insoluble in aqueous buffers and was
not active at a concentration of 4.83 mM in AlphaScreen or
14.5 mM in the PSMA enzyme inhibition assay. With limited
water solubility, peptide 564, at a concentration of 55.5 mM, could
not inhibit the PSMA enzymatic reaction. Interestingly, even with
a concentration of 1.07 mM, peptide 563 could not inhibit the
PSMA enzymatic reaction under our test conditions.
Quantitative studies of the affinity between peptide ligands
discovered by phage display and PSMA have only been
investigated by the PSMA enzyme inhibition assay
[32,40,41,42]. To the best of our knowledge, this is the first
investigation of affinities of peptide ligands for PSMA that are not
based on the inhibition of the enzymatic activity of PSMA. The
AlphaScreen technology is advantageous in assessing the affinity
between the peptide ligand and PSMA as it does not depend on
the inhibition of the PSMA enzymatic activity and it only requires
very low concentration (,nM) of PSMA. In fact, peptide 563
showed that it can bind PSMA with relatively high affinity (submM KD) but cannot inhibit the PSMA enzymatic reaction. For one
of the peptides which does inhibit the PSMA enzymatic activity,
peptide 562, the IC50 value (IC50 = 661 mM) is relatively higher
than the IC50 of aforementioned peptide ligand discovered by
Aggarwal et al. (IC50 = 23 mM). The Peptide-562-tetramer (5624,
Figure 6) only gave 2-fold improvement with an approximate IC50
value of 311 mM (95% confidence intervals: 267–363 mM,
Figure 5B). In comparison, both Aggarwal et al. and Banerjee et
al. [43] showed ,10-fold improvement on the PSMA enzyme

the peptides 562 and 563 discovered through phage display library
are indeed highly-specific PSMA-binding peptides.

Binding Affinities by AlphaScreen and PSMA enzyme
assays
AlphaScreen is a bead-based non-radioactive homogenous
proximity assay and has been used to study both strong (,nM
KD) and weak (,mM KD) interactions between biomolecules.
Because AlphaScreen is a homogenous assay, it is of particular
value in evaluating peptides with putative weak affinities that are
likely to be discovered from naı̈ve libraries. In previous work, the
KD-values derived from AlphaScreen assay were consistent with
those reported using other methods such as radio-ligand binding
assay, fluorescence polarization assay and surface plasmon
resonance (SPR) assays [30,31,37,38]. In our study, the biotinylated peptide 563 bound the streptavidin donor bead and the
PSMA-His6 bound the nickel chelate acceptor bead. Only when
the peptide binds to PSMA (thus bringing the two beads close to
each other), can the AlphaScreen (emission) signal be generated, in
which case, the singlet oxygen generated by the excitation at
680 nm on the donor bead can transfer energy to the adjacent
acceptor bead and subsequently produce an emission signal at
520–620 nm.
To test the affinity of peptides discovered by phage display,
peptides 562, 563, 564, and 563-biotin were synthesized and
purified by RP-HPLC and tested for affinity in either AlphaScreen
or in a PSMA inhibition assay. The peptides bearing the relatively
hydrophobic consensus sequence EVPRLSLLAVFL were synthesized, but due to the extremely limited aqueous solubility they
were not tested. In the AlphaScreen binding assay, peptide 563,
564, and 565 were used to displace biotinylated peptide 563 with
concomitant loss in signal. The IC50 values were used to
approximate the KD between the displacing peptides and PSMA
(Figure 5A). Peptide 563 (IC50 = 708 nM, 95%) and 564
(IC50 = 1.72 mM, 95% confidence intervals: 1.09–2.71 mM) disPLOS ONE | www.plosone.org
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inhibitory activity with their multimeric PSMA-binding ligands
when comparing to the monomeric ones. Aggarwal et al. [32]
attributed such enhancement to the b-hairpin-like secondary
structure of the dimeric peptide ligand they made while Banerjee et
al. attributed it to the optimized long-linker (20 Å) incorporated in
their bivalent small-molecule-based ligand. For the sequences
discovered in this work, further studies on the secondary structure
of those sequences might elucidate the binding mode of residues
within the sequence.
Notably, the PSMA enzyme-inhibitory peptide 562 and PSMA
enzyme non-inhibitory peptide 563 may bind to PSMA at
different surface areas. Peptide 562, SHSFSVGSGDHSPFT, is
hydrophilic relative to the very hydrophobic peptide sequence,
EVPRLSLLAVFL, and these two peptides may bind to PSMA at
different surface areas as well. Thus a potential strategy to increase
affinity is a multimeric peptide ligand that would incorporate both
hydrophobic and hydrophilic sequences such that two or more
sequences could work synergistically for binding PSMA with high
affinity and high specificity. This strategy to target different surface
areas of the protein of interest has been applied in the fields of
phage displayed peptide libraries [44,45], OBOC (one-bead-onecompound) peptide libraries [46] and peptoid microarrays [47].

produce peptides of high affinity, three strong consensus sequences
did emerge, GDHSPFT, SHFSVGS and EVPRLSLLAVFL in
addition to several sequences that were not in consensus. One
interesting trend in the sequences was peptides that bound PSMA
but did not inhibit the enzymatic activity of the PSMA. The next
steps for these sequences would be affinity maturation. A ten-fold
improvement of sequence GRFLTGGTGRLLRIS, with its IC50
value of ,700 nM would result in a peptide with affinity that
would be suitable for the non-invasive diagnosis and staging of
PCa when labeled with the appropriate isotope for PET. This
sequence may even be suitable for conjugation to nanoparticles for
therapy of prostate cancer through the enhancement of affinity
through avidity.

Supporting Information
Table S1 DNA sequences of PSMA-targeted clones.
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